Orchestra Biomed Holdings, Inc. (OBIO) — SEC Filings
Orchestra Biomed Holdings, Inc. (OBIO) — 33 SEC filings. Latest: 8-K (Nov 13, 2025). Includes 16 8-K, 6 10-Q, 3 SC 13G.
View Orchestra Biomed Holdings, Inc. on SEC EDGAR
Overview
Orchestra Biomed Holdings, Inc. (OBIO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: Orchestra BioMed Holdings, Inc. reported a net loss of $20.828 million for the three months ended September 30, 2025, an increase from $15.426 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $58.946 million from $44.869 million in the prior y
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 30 neutral, 1 mixed. The dominant filing sentiment for Orchestra Biomed Holdings, Inc. is neutral.
Filing Type Overview
Orchestra Biomed Holdings, Inc. (OBIO) has filed 16 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 3 SC 13G, 1 SC 13D/A, 3 SC 13G/A with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of OBIO's 26 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $861K |
| Net Income | -$20.828M |
| EPS | N/A |
| Debt-to-Equity | 1.39 |
| Cash Position | $42.012M |
| Operating Margin | -2359.2% |
| Total Assets | $104.807M |
| Total Debt | $61.068M |
Key Executives
- Dr. Jonathan L. R. Roth
- Dr. Jonathan L. Weiswasser
Industry Context
Orchestra BioMed operates in the highly competitive and capital-intensive biotechnology sector. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success hinges on innovation, clinical trial outcomes, and the ability to secure substantial funding to bring novel therapies to market.
Top Tags
financials (5) · 8-K (4) · 10-Q (4) · medical-devices (3) · financial-reporting (3) · Biomedical (2) · R&D Spending (2) · Net Loss (2) · Clinical Trials (2) · Hypertension Treatment (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for Q3 2025 | $20.828M | Increased from $15.426M in Q3 2024 |
| Net loss for nine months ended Sept 30, 2025 | $58.946M | Increased from $44.869M in the same period of 2024 |
| Total revenue for Q3 2025 | $861K | Decreased from $987K in Q3 2024 |
| Research and development expenses for Q3 2025 | $14.027M | Increased from $11.595M in Q3 2024 |
| Cash and cash equivalents as of Sept 30, 2025 | $42.012M | Increased from $22.261M at Dec 31, 2024 |
| Proceeds from sale of common stock and pre-funded warrants | $57.780M | Net cash provided by financing activities for nine months ended Sept 30, 2025 |
| Proceeds from the royalty purchase agreement | $20.000M | Net cash provided by financing activities for nine months ended Sept 30, 2025 |
| Total liabilities as of Sept 30, 2025 | $61.068M | Increased from $43.215M at Dec 31, 2024 |
| Royalty purchase agreement liability | $16.167M | New liability as of Sept 30, 2025 |
| Net cash used in operating activities for nine months ended Sept 30, 2025 | $46.693M | Increased from $37.020M in the same period of 2024 |
| Net Loss | $38.118M | Increased by 29.46% for the six months ended June 30, 2025, from $29.443M in 2024. |
| Research and Development Expenses | $27.335M | Increased by 35.07% for the six months ended June 30, 2025, from $20.238M in 2024. |
| Total Revenue | $1.704M | Increased for the six months ended June 30, 2025, from $1.398M in 2024. |
| Cash and Cash Equivalents | $18.749M | Decreased from $22.261M at December 31, 2024, to June 30, 2025. |
| Net Cash Used in Operating Activities | $32.143M | For the six months ended June 30, 2025, compared to $23.320M in 2024. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Orchestra Biomed Holdings, Inc. (OBIO)?
Orchestra Biomed Holdings, Inc. has 33 recent SEC filings from Feb 2024 to Nov 2025, including 16 8-K, 6 10-Q, 3 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of OBIO filings?
Across 33 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 30 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Orchestra Biomed Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Orchestra Biomed Holdings, Inc. (OBIO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Orchestra Biomed Holdings, Inc.?
Key financial highlights from Orchestra Biomed Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for OBIO?
The investment thesis for OBIO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Orchestra Biomed Holdings, Inc.?
Key executives identified across Orchestra Biomed Holdings, Inc.'s filings include Dr. Jonathan L. R. Roth, Dr. Jonathan L. Weiswasser.
What are the main risk factors for Orchestra Biomed Holdings, Inc. stock?
Of OBIO's 26 assessed filings, 2 were flagged high-risk, 11 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Orchestra Biomed Holdings, Inc.?
Forward guidance and predictions for Orchestra Biomed Holdings, Inc. are extracted from SEC filings as they are enriched.